vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
High Point
North Carolina
27265
United States
Tel: 336-841-0300 ext 100
Fax: 336-841-0310
Website: http://vtvtherapeutics.com/
140 articles with vTv Therapeutics Inc.
-
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
3/6/2023
vTv Therapeutics Inc. today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments.
-
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
2/1/2023
vTv Therapeutics Inc., a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, announced the appointment of Elizabeth Keiley as Executive Vice President and General Counsel, effective immediately.
-
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
12/13/2022
vTv Therapeutics Inc. today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately.
-
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
11/10/2022
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.
-
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
8/15/2022
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate developments.
-
Summit Therapeutics Inc. announced that Dr. Maky Zangenah, DDS, has been named co-Chief Executive Officer, and Paul Sekhri has risen to the title of CEO at vTv Therapeutics.
-
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
6/4/2022
vTv Therapeutics Inc. announced that the results from the JDRF-supported mechanistic study assessing effects of TTP399 on ketones during acute insulin withdrawal were published in the Diabetes Obesity and Metabolism journal and presented at The American Diabetes Association's 82nd Scientific Sessions on June 5th.
-
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
-
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
6/1/2022
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”).
-
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
5/12/2022
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs.
-
Noted Harvard researcher Doug Melton is heading to Vertex Pharmaceuticals to head up investigations into potential transformative treatments for type 1 diabetes.
-
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
3/30/2022
vTv Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on the progress of its clinical programs.
-
Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.
-
vTv Therapeutics Announces CEO Transition
3/3/2022
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive Officer.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
-
vTv Therapeutics Shares Updated Corporate Presentation
1/13/2022
vTv Therapeutics Inc. is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.
-
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company's future growth.
-
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
12/6/2021
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes, today announced the prioritization of its lead program TTP399 as it gears up for Phase 3 pivotal trials.
-
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.